Detecting Adverse Respiratory Events: A Comparison of the Effectiveness of Modern Respiratory Sensors

Sean Ermer, B.S., Lara Brewer, Ph.D, and Joseph Orr, Ph.D
Department of Bioengineering in Anesthesiology, University of Utah, Utah

Abstract: The underlying problem for two of the three most common patterns of unexpected hospital deaths (PUHD) is hypoventilation. Current methods of post-operative respiratory monitoring give delayed signals and have a high false positive rate leading nurses to ignore alarms. We hypothesize there exists a combination of low cost sensors which are capable of providing real time feedback and alarms regarding obstructive sleep apnea and ventilatory depression. Such a monitor would be useful during space travel when monitoring personnel are limited following an injury or if astronauts were to be sedated during extended travel.

Methods: Twenty-six subjects were recruited to participate in a study of the effects of Propofol and Remifentanil. Throughout the day, these patients were exposed to varying levels of both drugs simultaneously via target controlled infusions. These patients were attached to breathing and oxygen monitors including chest bands, pulse oximeters, nasal pressure sensors, CO₂ capnography, breathing microphones, and thermistors. The patients were then observed for types of apnea or ventilatory depression.

Results: The study is currently ongoing however preliminary analyses of the data indicate multiple low cost sensors are capable of detecting breathing as well as obstructive events and apnea. Conclusion: Using only a combination of low cost sensors, we can provide real time respiratory event data to nurses and practitioners.

INTRODUCTION & BACKGROUND

The underlying problem for two of the three most common patterns of unexpected hospital deaths (PUHD) is hypoventilation. Type II PUHD (CO₂ narcosis) involves a reduction in respiratory rate and/or tidal volume, and if supplemental oxygen is being provided, a pulse oximeter will not detect the problem until the hypercarbia is significantly advanced and the patient is near respiratory arrest. Type III PUHD is induced by obstructive sleep apnea in the presence of arousal failure, and is recognized as a repetitive sequence of cyclic apneas and self-arousals which precede the final apnea. A pulse oximeter alarms with each apneic period and will likely be interpreted as generating many false positive alarms. The risk of opioid-induced respiratory depression in postoperative patients is greatest in the first 24 hours after initiation of opioids, and opioids are the most commonly used drug for treating pain in the postoperative period.

These problems would be especially apparent in space travel where monitoring personnel are limited due to either sedation of crew members or an injury rendering the crew short-handed.

Respiratory depression is caused by drug-induced inhibition of the breathing control center of the brain stem. Partial to full airway obstruction is an anatomic problem...
involving the soft palate, tongue base, and/or epiglottis, caused by drug-induced decreases in airway patency and muscle tone. Sedatives and opioids depress the response to elevated CO₂ (reduced drive to breathe), worsen arousal, cause airway obstruction, and change sleep patterns⁴⁻⁸

In the postoperative period, most adverse respiratory events occur during the first 24 hours of opioid administration.² During this period, pulse oximeter monitoring, supplemental oxygen, incentive spirometry, and intermittent nursing observation are the primary interventions used to fend off adverse respiratory events. For inpatient monitoring, pulse oximetry is often inadequate. On a busy hospital floor, it is difficult to respond to multiple remote advisory pulse oximetry alarms. Pulse oximeter alarms are ignored because they have a high false-positive alarm rate due to movement artifact and displacement.⁹¹⁰ Pulse oximetry primarily monitors oxygenation instead of ventilation; the SpO₂ signal is a delayed indicator for apnea or hypopnea, particularly when supplemental oxygen is given. By the time the pulse oximeter alarms, an apneic patient is already in danger of hypoxia, brain injury and death.

Existing technologies may improve monitoring of adverse respiratory events in this setting, but are either costly or difficult to implement. For example, monitoring ventilation with capnography is expensive and it can be problematic to sample the exhaled gas with a face mask or nasal cannula in non-intubated patients.¹¹ Acoustic respiratory rate monitoring may be able to detect airway obstruction, but it is costly and may not have sufficient sensitivity to reliably detect apnea events.¹² We suggest that there is an urgent need for a low cost, reliable respiratory depression monitoring technique that can be integrated with the signals from the pulse oximeter to give additional physiologic information about a patient’s sufficiency of both ventilation and oxygenation.

Currently, we are exploring the value of integrating the information from a set of low-cost physiologic monitors that can be adapted to monitoring patients in a hospital floor setting. In addition to the red and infrared component signals that comprise the pulse oximeter plethysmography waveform, we intend to integrate information from motion sensors on the finger, head, abdomen, chest wall and bed, temperature, pressure and carbon dioxide sensors embedded in a nasal cannula and acoustic respiratory rate via a microphone on the throat. We will determine from the tested set the fewest number and least costly types of sensors that can be used to accurately identify and quantify ventilatory depression and airway obstruction, provide reliable measures of oxygenation AND ventilation, provide specific alarms, and avoid artifact. We will evaluate this multi-sensor set for volunteers who receive medications to produce ventilatory depression and/or partial to complete airway obstruction.

Our team previously characterized various effects of sedatives combined with opioids using drug interaction models. Specifically, we characterized the interaction of Propofol and Remifentanil on metrics of airway obstruction and intolerable ventilatory depression in volunteers.⁸ We defined intolerable ventilatory depression as a respiratory rate less than 4 breaths per minute and airway compromise as either partial (tidal volume less than 3 mL/kg in the presence of a respiratory effort) or complete
obstruction. Respiratory compromise was defined as either intolerable ventilatory depression or airway obstruction or both.

Using this model, predictions of respiratory compromise (0 to 100%) can be made for various dosing schemes of Propofol and remifentanil.8 (Figure 1). In general, dosing schemes that led to high concentration of Propofol were more likely to produce airway obstruction and higher doses of Remifentanil were more likely to produce intolerable ventilatory depression.

**METHODS**

A 20 gauge venous catheter was placed in an antecubital vein under local anesthesia (0.2 mL of 0.5% lidocaine) for the purpose of hydration and drug administration. The IV site was similar in all subjects. A maintenance infusion of 0.9% sodium chloride was administered at 1 ml/kg/hour throughout the study. Continuous infusions of Remifentanil and Propofol was infused into this peripheral IV.

Subjects were instrumented with a noninvasive blood pressure cuff, ECG leads, pulse oximeter(s), motion sensors, respiratory inductance plethysmography "chest bands", capnography nasal cannula, nasal gas pressure sensor, nasal thermistor and an acoustic respiratory rate sensor. These or similar monitors were placed to measure respiratory rate, tidal volume, end-tidal CO₂, SpO₂, blood pressure, body motion and heart rate. Chest and abdominal wall excursion were measured with the attached motion sensors and the respiratory inductance plethysmography bands. Changes in respiration pattern were displayed as real-time changes in CO₂ waveforms. A processed EEG monitor and/or a cerebral oximeter were optionally placed to record data for later analysis. A motion sensor was also placed on the bed. These devices were operational during the entire study day. Data from devices was electronically captured and recorded for later analysis. Continuous variables such as motion waveforms, pulse oximetry waveform, capnogram, and nasal airway pressure were digitized during data collection periods at 50-1000Hz during data collection periods at each target effect site concentration pair. Discrete variables were recorded every 5 seconds or as soon as data were available during data collection.

**Figure 1**: A: Dose of a drug, first as a bolus, then as a continuous infusion. B: effect site concentration (Ce) Corresponding to the given dose and C: Observed effect (sedation) for a single administered drug. Time points 1-5 correspond to a likelihood of effect in D: Effect and corresponding drug concentrations resulting in stated probabilities for respiratory compromise.
periods. Examples of discrete variables include heart rate, \(\text{SpO}_2\), Pet\(\text{CO}_2\), systolic blood pressure, diastolic blood pressure and respiratory rate. The tidal volume was occasionally measured with a differential pressure flow sensor attached to an anesthesia mask or mouthpiece in order to calibrate the respiratory inductance plethysmography bands.

Each subject received Propofol and Remifentanil. Similar to previously collected data from our volunteer laboratory (Kern et al, 2004), each drug was administered using a computer controlled (Stanpump\(^{14}\)) continuous infusion pump (Pump 22; Harvard Apparatus, Limited, Holliston, MA) to achieve selected target effect site concentrations. The effect site concentration refers to the drug concentration at the pharmacologic site of action. Pharmacokinetic parameters published by Minto et al.\(^{15}\) and Schnider et al.\(^{16}\) was used for Remifentanil and Propofol respectively.

We administered Propofol and Remifentanil pairs in a dose escalation scheme with small steps in order to creep up to the desired target effects of respiratory depression, airway obstruction and both effects while avoiding overshoot. To accomplish this, the Propofol was dosed in a range of 0.75 - 4 mcg/mL in dose escalation steps of approximately 0.5 mcg/mL. Remifentanil was dosed in a range of 0.75 to 4.0 ng/mL in escalation steps of approximately 0.25-0.5 ng/mL. If overshoot was observed for a given target effect site concentration pair, the target effect site concentrations were lowered so assessments could be made during the target effects of respiratory depression or airway obstruction or both. Once the drug concentration pair was identified which resulted in the target effects for a given subject, the steady state drug dose was maintained for a period of data collection.

To begin our analysis, we wanted to compare how well clinical apnea definitions correlated with minute volume data collected from our calibrated chest bands. A small literature search was performed for apnea definitions. Our data was plotted in a histogram according to these definitions and then plotted against minute volume. The data used in this comparison was primarily collected during low Propofol dosing schemes as we are interested in viewing the effectiveness of central apnea definitions.

Our next goal was to visualize the effectiveness in apnea detection of different cranial-centric monitors with respect to the clinical gold standard of Capnography monitoring. Data was aligned temporally in Matlab. Per the previous analysis, we defined apnea as a period of at least 15 seconds during which no breath was detected. Because of sample tube delay, the CO\(_2\) signal was shifted by 8 seconds before comparison to the other signals. Breath detection for the CO\(_2\) signal was done using the algorithm integrated into the capnometer (LoFlo, Philips, Wallingford CT). Breath detection for the nasal pressure and thermistor signals was performed using an algorithm we developed based on signal excursions above and below a baseline level.

**RESULTS**

A preliminary analysis of the data has revealed high correlation between certain respiratory monitors and specific breathing related ‘states’.
These breathing states are ‘normal’ breathing, complete airway obstruction (obstructive sleep apnea), partial airway obstruction (partial obstructive sleep apnea or snoring), and ventilatory depression (non-obstructive sleep apnea) characterized by a breathing rate of less than four breaths per minute. The figure below illustrates the some of the primary complex breathing patterns that we are interested in monitoring. Ventilatory depression was not included in the figure as it appears in the form of intermittent ‘normal’ breathing with occasionally reduced volume.

From this data we can already see multiple breathing patterns once we combine signals such as chest or abdomen excursion (ventilatory effort) and nasal pressure, expired CO₂, or thermistor readings (ventilatory success). In column A, we see what we would expect for each of these signals under normal breathing conditions; The chest and abdomen are in phase with each other, the biphasic nasal pressure signal is synced with ventilatory effort, and the expired CO₂ increases at expiration. Column B of figure 2 illustrates how these signals change during airway obstruction; Chest and abdomen bands are out of phase

![Figure 2](image)

**Figure 2**: Electronic signals collected during different breathing related ‘states’. The signals shown from top to bottom are: Chest band, abdomen band, nasal pressure, expired CO₂, and thermistor. The columns are one breath samples from the breathing states listed at the top of the figure.
with each other (paradoxical) while measures of ventilatory success are zeroed. Column C shows partial airway obstruction; the abdomen band becomes biphasic and only syncs with the chest during the latter half of the breath attempt where the obstruction was partially cleared. The lower magnitude nasal pressure is one indicator of the patient’s difficulty passing air.

Upon review of the literature, we found conflicting opinions regarding the definition of apnea. Time since last breath is the most common criteria for an apnea alarm. Scientific studies have used anywhere from 10-30 seconds in between breaths as the definition of apnea while clinical monitors can be programmed to detect lapses of 10-60 seconds in breathing. 9404 interbreath intervals were placed on a histogram shown in figure 3. The histogram follows a Gaussian distribution with \( \mu=9.58 \) and \( \lambda=14.10 \). In the histogram, 33% of the data lies above the 10 second cutoff. There appears to be some correlation between minute volume and interbreath interval, however there is an extremely large deviation of minute volumes as indicated by the green error bars. Error bars are bounded by two standard deviations from the mean.

Next we compared the effectiveness in apnea detection of the cranial-centric monitors shown in figure 1 (nasal pressure, thermistor) to the clinical Phillips monitor Capnography based detection. The results of this analysis are provided in table 1 and table 2. Table 1 depicts the comparison when the Propofol dose was low (<1 mcg/mL). Table 2 depicts the comparison when Remifentanil dose was low (<1 ng/mL). Data is shown as normalized percentages. True positive is defined as an apnea flag present in both signal 1 and signal 2. True negative is defined no apnea.

![Figure 3](image-url)  
**Figure 3**: Histogram of 9404 interbreath intervals. The histogram follows a Gaussian distribution with \( \mu=9.58 \) and \( \lambda=14.10 \). Minute volume is plotted on the second Y-axis. Some correlation exists but the variance is large.
flag in either signal 1 or 2. False positive is defined as an apnea flag in signal 1 with no apnea flag in signal 2. False negative is defined as no apnea flag in signal 1 and an apnea flag in signal 2.

CONCLUSION

A low cost, accurate, and minimally sized respiratory monitor would be useful during space travel when personnel are limited following an injury/emergency procedure or if astronauts were to be sedated during extended voyages.

Overall, preliminary analysis of the signals has been successful in proving that within individual patients, low cost signals exhibit discernible patterns during obstructive apnea, partial airway obstruction, and ventilatory depression.

Our analysis of apnea definitions and indicate that there is a need for a more robust respiratory monitor.

We’ve shown that there is at least moderate correlation between our cranial-centric sensors and the clinical standard of Capnography. Discrepancies in detection rate between these sensors can be attributed to a number of factors. To begin with, neither algorithm is perfect. While the overall number of breaths and apneas detected by each signal was similar, an incorrect breath assessment may result in an incorrect apnea flag. Capnography monitoring is especially prone to false positive breath detections when breathing rate is low—as in this study. Additionally, the comparison is being made between two sensors placed on the face and a side stream Capnometer. While attempts were made to temporally align the signal, the time delay is the Capnometer is dependent on

<table>
<thead>
<tr>
<th>Signal 1</th>
<th>Signal 2</th>
<th>True Positive</th>
<th>True Negative</th>
<th>False Positive</th>
<th>False Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal Pressure</td>
<td>Capnography</td>
<td>0.13</td>
<td>0.66</td>
<td>0.15</td>
<td>0.07</td>
</tr>
<tr>
<td>Thermistor</td>
<td>Capnography</td>
<td>0.08</td>
<td>0.73</td>
<td>0.07</td>
<td>0.12</td>
</tr>
<tr>
<td>Nasal Pressure</td>
<td>Thermistor</td>
<td>0.05</td>
<td>0.78</td>
<td>0.10</td>
<td>0.08</td>
</tr>
</tbody>
</table>

**Table 1**: Comparison of apnea detection in cranial centric monitors. This comparison was made during low Propofol dosing schemes (Propofol <1 mcg/mL).

<table>
<thead>
<tr>
<th>Signal 1</th>
<th>Signal 2</th>
<th>Positive</th>
<th>Negative</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal Pressure</td>
<td>Capnography</td>
<td>0.05</td>
<td>0.78</td>
<td>0.14</td>
<td>0.03</td>
</tr>
<tr>
<td>Thermistor</td>
<td>Capnography</td>
<td>0.02</td>
<td>0.88</td>
<td>0.04</td>
<td>0.06</td>
</tr>
<tr>
<td>Nasal Pressure</td>
<td>Thermistor</td>
<td>0.03</td>
<td>0.77</td>
<td>0.03</td>
<td>0.16</td>
</tr>
</tbody>
</table>

correlation with minute volumes also the rate of flow through the nose. Finally,

**Table 2**: Comparison of apnea detection in cranial centric monitors. This comparison was made during low Remifentanil dosing schemes (Remifentanil <1 mcg/mL).
the measured signals are fundamentally different. Capnometry measures gas concentration but is not dependent on volume or rate of gas flow. Nasal pressure and thermistor are sensitive to gas flow and volume and position of the cannula prongs in the nares.

ACKNOWLEDGEMENTS

I would like to thank the Rocky Mountain Space Grant Consortium for providing funding in order to pursue this research.

I would also like to thank those individuals who are currently assisting not only in data collection and planning but also in general advice during this study. Those individuals are Soeren Hoehe, Kelly Smith, Ken Johnson, and Julia White.

REFERENCES


16. Egan TD, Kern SE, Muir KT, White J. Remifentanil by bolus injection: a safety, pharmacokinetic,